Cited 40 times in
Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 방동식 | - |
dc.date.accessioned | 2015-05-19T16:59:22Z | - |
dc.date.available | 2015-05-19T16:59:22Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0923-1811 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/107318 | - |
dc.description.abstract | BACKGROUND: Anti-TNFalpha antibodies have been used for treating inflammation in patients. But, more effective and safer drugs need to be developed for improved future therapeutic use. OBJECTIVES: To inhibit the expression of TNFalpha, we used small interfering RNAs (siRNAs) to reduce over expression of TNFalpha in vitro in cell cultures and in an in vivo Behcet's disease-like (BD) mouse model for amelioration of chronic inflammation. METHODS: TNFalpha siRNA was injected intraperitoneally twice with a 1-week interval. To compare the efficacy of TNFalpha siRNA versus an anti-TNFalpha antibody, Infliximab and Etanercept were administered to symptomatic mice with inflamed tissue. RESULTS: Intraperitoneal delivery of TNFalpha siRNA effectively decreased BD symptoms in 18 of 32 cases (56.3%). Scrambled siRNA treatment decreased BD symptoms in 2 of 19 cases (10.5%). Infliximab was effective in 11 of 27 cases (40.7%) and Etanercept was also effective in 9 of 25 cases (36.0%) at the end of the second week after treatment. TNFalpha siRNA reduced serum levels of TNFalpha (1.57 +/- 0.43pg/ml), compared to levels in mice not injected (84.02 +/- 24.59pg/ml) (p<0.01) or scramble injected (118.89 +/- 20.08pg/ml) (p<0.01). After single injection of TNFalpha siRNA, improvement of BD symptoms showed at 9 +/- 7th day on an average, contrary, in Infliximab injected group, improvement was apparent at 15 +/- 4th day after injection (p<0.05). CONCLUSION: We show that siRNAs can be employed to inhibit cytokine gene expression in an in vivo disease mouse model. This inhibition may, therefore, be attributed to the improvement of inflammatory symptoms. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 87~97 | - |
dc.relation.isPartOf | JOURNAL OF DERMATOLOGICAL SCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Anti-Inflammatory Agents/pharmacology | - |
dc.subject.MESH | Anti-Inflammatory Agents/therapeutic use | - |
dc.subject.MESH | Antibodies, Monoclonal/pharmacology | - |
dc.subject.MESH | Antibodies, Monoclonal/therapeutic use | - |
dc.subject.MESH | Behcet Syndrome/drug therapy* | - |
dc.subject.MESH | Behcet Syndrome/metabolism | - |
dc.subject.MESH | Behcet Syndrome/virology* | - |
dc.subject.MESH | Cells, Cultured | - |
dc.subject.MESH | Cytokines/metabolism | - |
dc.subject.MESH | Disease Models, Animal | - |
dc.subject.MESH | Etanercept | - |
dc.subject.MESH | Immunoglobulin G/pharmacology | - |
dc.subject.MESH | Immunoglobulin G/therapeutic use | - |
dc.subject.MESH | Infliximab | - |
dc.subject.MESH | Lipopolysaccharides/metabolism | - |
dc.subject.MESH | Macrophages/drug effects | - |
dc.subject.MESH | Macrophages/metabolism | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Inbred ICR | - |
dc.subject.MESH | RNA, Small Interfering/pharmacology | - |
dc.subject.MESH | RNA, Small Interfering/therapeutic use* | - |
dc.subject.MESH | Receptors, Tumor Necrosis Factor/therapeutic use | - |
dc.subject.MESH | Simplexvirus/pathogenicity* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/antagonists & inhibitors | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/genetics* | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/metabolism | - |
dc.title | Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Dermatology (피부과학) | - |
dc.contributor.googleauthor | Bunsoon Choi | - |
dc.contributor.googleauthor | Yunchung Hwang | - |
dc.contributor.googleauthor | Hyuk Jae Kwon | - |
dc.contributor.googleauthor | Eun-So Lee | - |
dc.contributor.googleauthor | Kyung Sook Park | - |
dc.contributor.googleauthor | Dongsik Bang | - |
dc.contributor.googleauthor | Sungnack Lee | - |
dc.contributor.googleauthor | Seonghyang Sohn | - |
dc.identifier.doi | 10.1016/j.jdermsci.2008.05.001 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01784 | - |
dc.relation.journalcode | J01370 | - |
dc.identifier.eissn | 1873-569X | - |
dc.identifier.pmid | 18585901 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0923181108001540 | - |
dc.subject.keyword | TNF alpha | - |
dc.subject.keyword | SiRNA | - |
dc.subject.keyword | Herpes simplex virus | - |
dc.subject.keyword | Mouse model | - |
dc.subject.keyword | Behcet's disease | - |
dc.subject.keyword | In vivo | - |
dc.contributor.alternativeName | Bang, Dong Sik | - |
dc.contributor.affiliatedAuthor | Bang, Dong Sik | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 52 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 87 | - |
dc.citation.endPage | 97 | - |
dc.identifier.bibliographicCitation | JOURNAL OF DERMATOLOGICAL SCIENCE, Vol.52(2) : 87-97, 2008 | - |
dc.identifier.rimsid | 48287 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.